Inovio Pharma (INO)
$4.22
0.07 (1.69%)
INO Stock Quote Delayed 15 Minutes
Previous Close
$4.22
Market Cap
383.86M
PE Ratio
-3.70
EPS
-1.14
Volume (Avg. Vol.)
15.24M
Day's Range
4.16 - 4.55
52-Week Range
1.92 - 5.95
Dividend & Yield
N/A (N/A)
INO Stock Predictions, Articles, and Inovio Pharma News
Inovio’s Surge on a Coronavirus Vaccine Was Just Speculation
Investors sold off INO stock when they remembered that launching a coronavirus vaccine would take at least a few months.
What Inovio Pharma’s $100 Million Addition to Its Shelf Offering Means for INO Stock
Like many pharmaceutical companies, Inovio loses a lot of money. As of September 30, 2019, it had an accumulated deficit of $702 million, which means it’s lost $702 million over its history.
Pandemic Fears Not Enough to Buy Inovio Stock
INO stock initially enjoyed tremendous momentum due to the underlying small-cap pharmaceutical delivering a coronavirus vaccine. However, this is a story that has been repeated many times in the past, each time leading to disappointment.
3 Pros and 3 Cons For INO Stock Amid Chinese Coronavirus Outbreak
Several factors both cloud and bolster the narrative for INO stock. Ultimately though, the underlying company’s technology is worth a speculative gamble.
Inovio’s Pop and Drop Is a Lesson Against Chasing Headlines
The INO stock flash and crash should serve as a warning to traders trying to get rich off of every news development.
Novavax News: NVAX Stock Skyrockets 52% on Mystery China Virus
Novavax (NVAX) news for Tuesday concerning the spread of a virus in China has NVAX stock heading higher as more investors pick up the stock.
Inovio Pharmaceuticals Earnings: INO Stock Dips as Q4 Revenue Declines
INO stock is down more than 4% as Inovio Pharmaceuticals reported its quarterly earnings results, bringing in revenue that fell year-to-year.
Inovio Pharmaceuticals Inc (INO) Q4 Revenue Grew 3.5% Year-Over-Year
Inovio Pharmaceuticals (INO) posted its latest quarterly earnings results, which saw revenue grow more than 3% for the quarter and nearly 20% for the year.
Inovio Pharmaceuticals Inc (INO) Spikes on HIV Vaccine Trial Results
Inovia Pharmaceuticals Inc (INO) jumped more than 30% its HIV vaccine showed some of the highest overall rates of immune response ever.
Hottest Manufacturing Stocks Now – MRUS CALA INVN MNTX
The Manufacturing sector saw plenty of trading activity today, including the following leaders and losers.
40 Biotechnology Stocks to Sell Now
This week, the overall grades of 40 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
40 Biotechnology Stocks to Sell Now
The overall ratings of 40 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Stocks Rise on AT&T, Time Warner Merger Hype
In the end, the Dow Jones gained 0.4%, the S&P 500 gained 0.5%, the Nasdaq inched up 1% and the Russell 2000 ended 0.7% higher.
Biggest Movers in Manufacturing Stocks Now – MTL BEAV RXN BCRX
The Manufacturing sector saw plenty of trading activity today, including the following leaders and losers.
21 Biotechnology Stocks to Buy Now
This week, 21 Biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").
24 Biotechnology Stocks to Buy Now
24 Biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an "A" ("strong buy") or "B" overall ("buy").
Navellier Ratings
Powered by Portfolio GraderTotal Grade
C
